Literature DB >> 3227292

Clinical presentation and prognosis of gastrointestinal carcinoid tumours.

S M Sjöblom1.   

Abstract

Clinical data about 104 patients with gastrointestinal carcinoids emphasized the heterogeneous nature of these tumours in different organs. The sites of the primary tumours were the stomach in 12 (11%), the duodenum in 3 (3%), the small bowel in 48 (45%), the appendix in 28 (26%), the colon in 6 (6%), and the rectum in 6 cases (6%). Gastric carcinoids were multiple in 4 (33%) and small-bowel carcinoids in 11 cases (23%). None of the gastric, duodenal, or rectal carcinoids had generated metastases, as contrasted to 34 (72%) small-bowel carcinoids. Twelve patients had symptoms of the carcinoid syndrome caused by hepatic metastases from ileal (11) or appendiceal (1) primary tumours. At least two patients with duodenal carcinoids had Zollinger-Ellison syndrome produced by the tumours. The cumulative 5-year survival rate was 91-100% for gastric, appendiceal, and rectal carcinoids, 77% for small-bowel carcinoids, and 33% for colonic carcinoids. Resectable mesenteric lymph node metastases did not affect the 5-year survival of patients with small-bowel carcinoids as compared with the tumours confined to the bowel wall. Poor prognosis was associated with hepatic metastases at the time of diagnosis. Small-bowel carcinoids remain a challenge in clinical work because of their distinct metastatic propensity and problematic diagnosis.

Entities:  

Mesh:

Year:  1988        PMID: 3227292     DOI: 10.3109/00365528809090760

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  15 in total

1.  Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component.

Authors:  Patrick Veit-Haibach; Marc Schiesser; Jan Soyka; Klaus Strobel; Niklaus G Schaefer; Rolf Hesselmann; P-A Clavien; Thomas F Hany
Journal:  Eur Radiol       Date:  2010-08-15       Impact factor: 5.315

2.  [Neuroendocrine neoplasia of the stomach : What is new?]

Authors:  T Knösel; C Reiter; G Schubert-Fritschle; A Altendorf-Hofmann; T Kirchner
Journal:  Pathologe       Date:  2017-03       Impact factor: 1.011

3.  Dual tracer functional characterization of metastatic gastric carcinoid.

Authors:  Niraj Naswa; Punit Sharma; Shipra Agarwal; Rakesh Kumar; Chandrashekhar Bal
Journal:  Indian J Nucl Med       Date:  2013-01

Review 4.  The imaging features of small bowel tumours.

Authors:  Katherine van Ree; Peter Thurley; Rajeev Singh; Nicholas Hurst; Dominic Clark
Journal:  J Gastrointest Cancer       Date:  2012-09

5.  Observations on relationship between hypergastrinemia, multiple gastric carcinoids, and pancreatic mass.

Authors:  I M Modlin; C J Gilligan; G P Lawton; L H Tang; A B West; R Lindenberg
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

6.  Carcinoid valve disease.

Authors:  J Wells Askew; Heidi M Connolly
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-10

Review 7.  [Therapy of carcinoids of the stomach].

Authors:  H D Becker; A Gabriel
Journal:  Langenbecks Arch Chir       Date:  1996

Review 8.  Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor.

Authors:  Linda Zhang; Junko Ozao; Richard Warner; Celia Divino
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

9.  Asymptomatic Ileal Neuroendocrine "Carcinoid" Tumor Incidentally Diagnosed on Colorectal Cancer Screening Colonoscopy: Does Routine TI Intubation Matter?

Authors:  Ali Zakaria; Lynna Alnimer; Gregory Byrd; Marc Piper; Michael Raphael; Bradley Warren; Michael Piper
Journal:  Case Rep Gastrointest Med       Date:  2021-02-03

10.  Gastrointestinal carcinoid tumors: factors that predict outcome.

Authors:  Jamie J Van Gompel; Rebecca S Sippel; Tom F Warner; Herbert Chen
Journal:  World J Surg       Date:  2004-03-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.